Update date
13 Mar 2026
EUPRAXIA PHARMACEUTICALS INC. financial metrics
Period Q4 2025 · Filed 13 Mar 2026
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Common Stock, Shares, Outstanding |
51,939,206
Period-end balance · 31 Dec 2025
|
+46% |
| Common Stock, Value, Issued |
$195,406,895
Period-end balance · 31 Dec 2025
|
+68% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$942,201
Period-end balance · 31 Dec 2025
|
+150% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$716,095
Period-end balance · 31 Dec 2025
|
+177% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$2,044,137
Period-end balance · 31 Dec 2025
|
+51% |
| Assets |
$86,150,008
Period-end balance · 31 Dec 2025
|
+147% |
| Assets, Current |
$85,098,550
Period-end balance · 31 Dec 2025
|
+147% |
| Cash and Cash Equivalents, at Carrying Value |
$80,563,482
Period-end balance · 31 Dec 2025
|
+143% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$80,563,482
Period-end balance · 31 Dec 2025
|
+143% |
| Common Stock, Par or Stated Value Per Share |
15
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares, Issued |
51,939,206
Period-end balance · 31 Dec 2025
|
+46% |
| Deferred Tax Assets, Net of Valuation Allowance |
$0
Period-end balance · 31 Dec 2025
|
|
| Deferred Tax Assets, Operating Loss Carryforwards |
$30,555,303
Period-end balance · 31 Dec 2025
|
+38% |
| Deferred Tax Assets, Valuation Allowance |
$43,366,083
Period-end balance · 31 Dec 2025
|
+38% |
| Lessee, Operating Lease, Liability, to be Paid |
$163,514
Period-end balance · 31 Dec 2025
|
+120% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$85,312
Period-end balance · 31 Dec 2025
|
+15% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$78,202
Period-end balance · 31 Dec 2025
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$9,152
Period-end balance · 31 Dec 2025
|
+248% |
| Liabilities |
$5,703,915
Period-end balance · 31 Dec 2025
|
+84% |
| Liabilities and Equity |
$86,150,008
Period-end balance · 31 Dec 2025
|
+147% |
| Liabilities, Current |
$5,628,005
Period-end balance · 31 Dec 2025
|
+81% |
| Operating Lease, Liability |
$154,362
Period-end balance · 31 Dec 2025
|
+115% |
| Operating Lease, Liability, Current |
$78,452
Period-end balance · 31 Dec 2025
|
+9.2% |
| Operating Lease, Liability, Noncurrent |
$75,910
Period-end balance · 31 Dec 2025
|
|
| Operating Lease, Right-of-Use Asset |
$152,697
Period-end balance · 31 Dec 2025
|
+128% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0605
Period-end balance · 31 Dec 2025
|
-33% |
| Preferred Stock, Shares Issued |
8,355,638
Period-end balance · 31 Dec 2025
|
-6.2% |
| Preferred Stock, Shares Outstanding |
8,355,638
Period-end balance · 31 Dec 2025
|
-6.2% |
| Property, Plant and Equipment, Gross |
$1,478,596
Period-end balance · 31 Dec 2025
|
+81% |
| Property, Plant and Equipment, Net |
$834,429
Period-end balance · 31 Dec 2025
|
+133% |
| Retained Earnings (Accumulated Deficit) |
$169,579,974
Period-end balance · 31 Dec 2025
|
-29% |
| Stockholders' Equity Attributable to Parent |
$82,041,436
Period-end balance · 31 Dec 2025
|
+146% |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
$80,446,093
Period-end balance · 31 Dec 2025
|
+153% |
Comparisons, sources and research notes
Sources and sharing
EPRX - EUPRAXIA PHARMACEUTICALS INC. Financial Facts
- Context
- Latest metrics period: Q4 2025
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for EPRX - EUPRAXIA PHARMACEUTICALS INC.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 13 Mar 2026.
Filing notes and source
Key facts
- EPRX - EUPRAXIA PHARMACEUTICALS INC. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q4 2025.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Data confidence notes
- Free cash flow unavailable: operating cash flow or capex is missing
- Valuation unavailable: free cash flow is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first